7TN0 image
Deposition Date 2022-01-20
Release Date 2022-02-02
Last Version Date 2024-11-20
Entry Detail
PDB ID:
7TN0
Title:
SARS-CoV-2 Omicron RBD in complex with human ACE2 and S304 Fab and S309 Fab
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.85 Å
R-Value Free:
0.26
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:S309 light chain
Chain IDs:A, D
Chain Length:214
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:S309 heavy chain
Chain IDs:B, C
Chain Length:230
Number of Molecules:2
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Angiotensin-converting enzyme 2
Gene (Uniprot):ACE2
Chain IDs:E, F
Chain Length:601
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:S304 Fab light chain
Chain IDs:G, K (auth: N)
Chain Length:215
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:S304 Fab heavy chain
Chain IDs:H, J (auth: M)
Chain Length:223
Number of Molecules:2
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Spike protein S1
Gene (Uniprot):S
Chain IDs:I, L (auth: S)
Chain Length:216
Number of Molecules:2
Biological Source:Severe acute respiratory syndrome coronavirus 2
Primary Citation
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.
Science 375 864 868 (2022)
PMID: 35076256 DOI: 10.1126/science.abn8652

Abstact

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern evades antibody-mediated immunity that comes from vaccination or infection with earlier variants due to accumulation of numerous spike mutations. To understand the Omicron antigenic shift, we determined cryo-electron microscopy and x-ray crystal structures of the spike protein and the receptor-binding domain bound to the broadly neutralizing sarbecovirus monoclonal antibody (mAb) S309 (the parent mAb of sotrovimab) and to the human ACE2 receptor. We provide a blueprint for understanding the marked reduction of binding of other therapeutic mAbs that leads to dampened neutralizing activity. Remodeling of interactions between the Omicron receptor-binding domain and human ACE2 likely explains the enhanced affinity for the host receptor relative to the ancestral virus.

Legend

Protein

Chemical

Disease

Primary Citation of related structures